Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12605421 | 1.00 | SIGMAR1 (0.47) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL12605420 | 1.00 | SIGMAR1 (0.47) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL4402941 | 0.94 | SIGMAR1 (0.50) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL17722606 | 0.92 | SIGMAR1 (0.53) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL17722640 | 0.92 | SIGMAR1 (0.53) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL17722612 | 0.92 | SIGMAR1 (0.53) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL24688441 | 0.92 | SIGMAR1 (0.41) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL19707449 | 0.92 | SIGMAR1 (0.41) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL25862156 | 0.87 | KMT2A (0.41) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL26280673 | 0.85 | KMT2A (0.47) | SIGMAR1CHRM5CHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230250063-A1 | PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230142338-A1 | THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220127258-A1 | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2022-04-28 | — | — | US | disclosed |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20200131123-A1 | INDOLE-FORMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-04-30 | — | — | US | disclosed |
| US-10434096-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190152958-A1 | PHARMACEUTICAL USES OF PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190099411-A1 | TYROSINE KINASE INHIBITORS | MIDCAP FINANCIAL TRUST | 2019-04-04 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7576092-B2 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | MERCK SHARP & DOHME CORP. | 2009-04-23 | — | — | US | disclosed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | AGOURON PHARMACEUTICALS, INC | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152958-A1 | PHARMACEUTICAL USES OF PYRIDINE CARBOXAMIDE DERIVATIVES | CASK, PDXK, NADK | SIGMAR1 3008/4885CHRM5 768/4885CHRM1 1396/4885 |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | SIGMAR1 393/4885CHRM5 416/4885CHRM1 280/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | SIGMAR1 2647/4885CHRM5 1709/4885CHRM1 1155/4885 |
| US-20070027118-A1 | Novel compounds of amino sulfonyl derivatives | HSD11B1, HSD11B2, HSD17B11 | SIGMAR1 449/4885CHRM5 3690/4885CHRM1 2569/4885 |
| US-20190099411-A1 | TYROSINE KINASE INHIBITORS | TYRO3, AXL, RET | SIGMAR1 874/4885CHRM5 924/4885CHRM1 808/4885 |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | SIGMAR1 103/4885CHRM5 476/4885CHRM1 222/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | SIGMAR1 3391/4885CHRM5 4876/4885CHRM1 4880/4885 |
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | HRH4, HRH1, HRH2 | SIGMAR1 1609/4885CHRM5 412/4885CHRM1 446/4885 |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | SIRT1, NQO1, TXNRD2 | SIGMAR1 4654/4885CHRM5 1658/4885CHRM1 2037/4885 |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | SIGMAR1 1349/4885CHRM5 4335/4885CHRM1 4649/4885 |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | HRH4, HRH2, HRH3 | SIGMAR1 1629/4885CHRM5 163/4885CHRM1 209/4885 |
| US-10434096-B2 | Tyrosine kinase inhibitors | TYRO3, AXL, RET | SIGMAR1 874/4885CHRM5 924/4885CHRM1 808/4885 |
| US-20230142338-A1 | THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN3, NSUN2 | SIGMAR1 2067/4885CHRM5 4865/4885CHRM1 4860/4885 |
| US-20200131123-A1 | INDOLE-FORMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | TPH1, TPH2, PAH | SIGMAR1 2524/4885CHRM5 1335/4885CHRM1 1464/4885 |
| US-20230250063-A1 | PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR2, FPR1, FPR3 | SIGMAR1 990/4885CHRM5 599/4885CHRM1 594/4885 |
| US-20220127258-A1 | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP46A1, NR1H4, CYP7A1 | SIGMAR1 935/4885CHRM5 2313/4885CHRM1 2024/4885 |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | CASK, PDXK, NADK | SIGMAR1 3008/4885CHRM5 768/4885CHRM1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.